Citations

Mayo Clinic

Clear

884 citation(s) found for "Dallas, S L".

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Fleischmann, Roy , Mysler, Eduardo , Greenwald, Maria , Ytterberg, Steven R. , Koch, Gary G., Bhatt, Deepak L. , Wang, Cunshan, Mikuls, Ted R. , Chen, All‐shine, Connell, Carol A., Woolcott, John , Menon, Sujatha, Chen, Yan , Lee, Kristen , Fleischmann, Roy , Mikuls, Ted R , Szekanecz, Zoltán , Bhatt, Deepak L , Charles‐Schoeman, Christina

Arthritis & Rheumatology | March 14, 2024 | Volume: 76 | Issue: 8 | Pages: 1218-1229

10.1002/art.42846 | PMID 38481002 Get It

Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. Methods Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient‐years) by 6‐month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. Results Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6‐month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m 2 , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. Conclusion Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer
Deimling, Markus von , Mertens, Laura S. , Furrer, Marc A. , Li, Roger , Tendijck, Guus A. H. , Mari, Andrea , Tully, Karl H. , D’Andrea, David , Velev, Maud , Gallioli, Andrea , Albisinni, Simone , Mori, Keiichiro , Khanna, Abhinav, Rink, Michael , Fisch, Margit, Kiss, Bernhard , Collaborators, CLIPOLY Study Group, Antonelli, Alessandro , von Deimling, Markus , Furrer, Marc , Mari, Andrea , Pichler, Renate , Moschini, Marco , Tully, Karl H , D'Andrea, David , Laukhtina, Ekaterina , Del Giudice, Francesco , Gallioli, Andrea , Albisinni, Simone , Mori, Keiichiro , Lotan, Yair , Kiss, Bernhard , Antonelli, Alessandro , Li, Roger , Mertens, Laura S , Taylor, Jacob , Crocetto, Felice , Maas, Moritz , Pichler, Renate , Moschini, Marco , Laukhtina, Ekaterina , Marcq, Gautier , Minervini, Andrea , Black, Peter C. , Lotan, Yair , Spiess, Philippe E. , Shariat, Shahrokh F. , Pradère, Benjamin , Collaborators, CLIPOLY Study Group

BJU International | March 12, 2024 | Volume: 134 | Issue: 1 | Pages: 119-127

10.1111/bju.16319 | PMID 38470089 Get It

Objective To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node‐positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. Patients and Methods We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose‐dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1–3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni‐ and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer‐specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. Results Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles ( P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2‐year OS estimates were 63% (95% confidence interval [CI] 0.53–0.74) and 63% (95% CI 0.58–0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni‐ or multivariable Cox regression analyses. Conclusion Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.
Structural bases for stoichiometry‐selective calcium potentiation of a neuronal nicotinic receptor
Mazzaferro, Simone , Kang, Guipeun , Natarajan, Kathiresan , Hibbs, Ryan , Sine, Steven M. , Hibbs, Ryan E

British Journal of Pharmacology | March 8, 2024 | Volume: 181 | Issue: 13 | Pages: 1973-1992

10.1111/bph.16321 | PMID 38454578 Get It

Background and Purpose α4β2 nicotinic acetylcholine (nACh) receptors assemble in two stoichiometric forms, one of which is potentiated by calcium. The sites of calcium binding that underpin potentiation are not known. Experimental Approach To identify calcium binding sites, we applied cryo‐electron microscopy (cryo‐EM) and molecular dynamics (MD) simulations to each stoichiometric form of the α4β2 nACh receptor in the presence of calcium ions. To test whether the identified calcium sites are linked to potentiation, we generated mutants of anionic residues at the sites, expressed wild type and mutant receptors in clonal mammalian fibroblasts, and recorded ACh‐elicited single‐channel currents with or without calcium. Key Results Both cryo‐EM and MD simulations show calcium bound to a site between the extracellular and transmembrane domains of each α4 subunit (ECD‐TMD site). Substituting alanine for anionic residues at the ECD‐TMD site abolishes stoichiometry‐selective calcium potentiation, as monitored by single‐channel patch clamp electrophysiology. Additionally, MD simulation reveals calcium association at subunit interfaces within the extracellular domain. Substituting alanine for anionic residues at the ECD sites reduces or abolishes stoichiometry‐selective calcium potentiation. Conclusions and Implications Stoichiometry‐selective calcium potentiation of the α4β2 nACh receptor is achieved by calcium association with topographically distinct sites framed by anionic residues within the α4 subunit and between the α4 and β2 subunits. Stoichiometry‐selective calcium potentiation could result from the greater number of calcium sites in the stoichiometric form with three rather than two α4 subunits. The results are relevant to modulation of signalling via α4β2 nACh receptors in physiological and pathophysiological conditions.
Analysis of editor in chief gender and associated journal variables among 126 pathology journals
Wang, Dayle K. , Clark, Landon M. , Adkins, Brian D. , Khan, Shazia S , Booth, Garrett S. , Jacobs, Jeremy W. , Adkins, Brian David , Booth, Garrett , Jacobs, Jeremy W , Stephens, Laura D.

American Journal of Clinical Pathology | March 4, 2024 | Volume: 162 | Issue: 1 | Pages: 12-16

10.1093/ajcp/aqae018 | PMID 38437878 Get It

Abstract Objectives Gender equity studies have shown that women are underrepresented in journal editor in chief positions, which confer major professional opportunities and influence. We sought to systematically investigate editor in chief gender and journal attributes within pathology. Methods We constructed a journal data set using the Scimago Journal & Country Rank and Clarivate Journal Citation Reports databases. We also included official journals of the major medical societies for the 12 pathology subspecialties recognized by the Association of American Medical Colleges. The final data set included 126 journals. We obtained editor in chief gender, impact factor, publication model (ie, hybrid access vs open access), year of founding, and geographic location for all included pathology journals. Results Women made up only 18% of the 141 total editor in chief positions. This inequity was present irrespective of all pathology journal variables studied. Among 10 journals with 2 editor in chief positions, 5 had only men and 5 had 1 man and 1 woman. All 3 journals with 3 editor in chief positions had 2 men and 1 woman. Conclusions Women are significantly underrepresented among editor in chiefs across pathology journals. Journals and affiliated members should advocate for diversity among these influential positions, given their impact on research, science, and medicine.
Equitable Interoperability Through Precise Control of Sensitive Health Information: An Emerging Pathway to Health Equity
Petersen, Carolyn , Galvin, Hannah K. , Lehmann, Christoph U. , Sharko, Marianne , Lehmann, Christoph U , Petersen, Carolyn

Annals of Internal Medicine | March 4, 2024 | Volume: 177 | Issue: 3 | Pages: 387-388

10.7326/m23-2876 | PMID 38437704 Get It

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
Jacobs, Jeremy W. , Stephens, Laura D. , Chooljian, David M. , Sharma, Deva , Adkins, Brian D. , Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura

American Journal of Hematology | February 27, 2024 | Volume: 99 | Issue: 6 | Pages: 1016-1018

10.1002/ajh.27275 | PMID 38409818 Get It

Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
Pemmaraju, Naveen , Madanat, Yazan F. , Rizzieri, David A. , Fazal, Salman, Rampal, Raajit K. , Mannis, Gabriel N. , Wang, Eunice S. , Foran, James M. , Lane, Andrew A. , Rizzieri, David A , Rampal, Raajit K , Foran, James M , Wang, Eunice S. , Madanat, Yazan , Lane, Andrew A

Leukemia & Lymphoma | February 23, 2024 | Volume: 65 | Issue: 5 | Pages: 548-559

10.1080/10428194.2024.2305288 | PMID 38391126 Get It

Factors Affecting Selection of TraineE for Neurointervention (FASTEN)
Elfil, Mohamed , Ghozy, Sherief , Elmashad, Ahmed , Al‐Bayati, Alhamza R , Alaraj, Ali , Brook, Allan , Kam, Anthony W. , Waldau, Ben , Altschul, David , Parrella, David Turkel, Tóth, Gábor , Jindal, Gaurav , Shaikh, Hamza , Dolia, Jaydevsinh , Thomas, Justin, Kim, Louis J. , Harrigan, Mark R. , Kole, Max , Mokin, Max, Janjua, Nazli , Zaidat, Osama O. , Youssef, Patrick , Khandelwal, Priyank , Wang, Qingliang Tony, Szeder, Viktor , Tanweer, Omar , Jankowitz, Brian T. , Heit, Jeremy J. , Williamson, Richard , Kass‐Hout, Tareq , Crowley, R. Webster , El‐Ghanem, Mohammad , Kam, Anthony , Ghozy, Sherief , Siddiqui, Adnan H , Al-Bayati, Alhamza , Alaraj, Ali , Kam, Anthony W , Matouk, Charles , Schirmer, Clemens M , Altschul, David J , Shaikh, Hamza A , Amuluru, Krishna , Grandhi, Ramesh , Hanel, Ricardo A , Ortega-Gutierrez, Santiago , Nguyen, Thanh N , Szeder, Viktor , Heit, Jeremy J , Al-Mufti, Fawaz , Elfil, Mohamed , Dolia, Jaidevsinh , Morsi, Rami Z. , Siddiqui, Adnan H. , Chatterjee, Arindam R , Patsalides, Athos T , Prestigiacomo, Charles Joseph , Matouk, Charles , Schirmer, Clemens M. , Fifi, Johanna T , Fraser, Justin F , Kim, Louis J. , Amans, Matthew R. , Abraham, Michael G. , Jumaa, Mouhammad , Grandhi, Ramesh , Hanel, Ricardó A. , Kellogg, Ryan Thomson , Sheth, Sunil A , Nguyen, Thanh N. , Hu, Yin , Yoo, Albert J. , Al‐Mufti, Fawaz

Interventional Neuroradiology | February 23, 2024 | Volume: 32 | Issue: 4 | Pages: 1253-1260

10.1177/15910199241232726 | PMID 38389309 Get It

Background and importance Neurointervention is a very competitive specialty in the United States due to the limited number of training spots and the larger pool of applicants. The training standards are continuously updated to ensure solid training experiences. Factors affecting candidate(s) selection have not been fully established yet. Our study aims to investigate the factors influencing the selection process. Methods A 52-question survey was distributed to 93 program directors (PDs). The survey consisted of six categories: (a) Program characteristics, (b) Candidate demographics, (c) Educational credentials, (d) Personal traits, (e) Research and extracurricular activities, and (f) Overall final set of characteristics. The response rate was 59.1%. As per the programs’ characteristics, neurosurgery was the most involved specialty in running the training programs (69%). Regarding demographics, the need for visa sponsorship held the greatest prominence with a mean score of 5.9 [standard deviation (SD) 2.9]. For the educational credentials, being a graduate from a neurosurgical residency and the institution where the candidate's residency training is/was scored the highest [5.4 (SD = 2.9), 5.4 (SD = 2.5), respectively]. Regarding the personal traits, assessment by faculty members achieved the highest score [8.9 (SD = 1)]. In terms of research/extracurricular activities, fluency in English had the highest score [7.2 (SD = 1.9)] followed by peer-reviewed/PubMed-indexed publications [6.4 (SD = 2.2)]. Conclusion Our survey investigated the factors influencing the final decision when choosing the future neurointerventional trainee, including demographic, educational, research, and extracurricular activities, which might serve as valuable guidance for both applicants and programs to refine the selection process.
Preliminary study on the dynamic positron emission tomography imaging with 11C‐ER176 to delineate macrophage activation in diabetic gastroparesis
Maalouf, Elisia, Khasawneh, Hala , Karbhari, Aashna , AlAsfoor, Shefaa , Breen‐Lyles, Margaret K., Bernard, Cheryl E., Rajan, Elizabeth , Farrugia, Gianrico , Lowe, Val J. , Goenka, Ajit H. , Grover, Madhusudan , Breen-Lyles, Margaret, Bernard, Cheryl, Goenka, Ajit, Khasawneh, Hala

Neurogastroenterology & Motility | February 20, 2024 | Volume: 36 | Issue: 5 | Pages: No page available

10.1111/nmo.14762 | PMID 38376247 Get It

AbstractBackgroundAnimal models and human data have suggested macrophage‐driven immune dysregulation in diabetic gastroparesis (DG). Translocator protein (TSPO) upregulation has been suggested to indicate activated state of macrophages and ER176 is a high affinity third generation TSPO‐specific radioligand. The aim of this study was to determine feasibility of dynamic 11C‐ER 176 PET to identify macrophage activation in DG.MethodsTwelve patients, all females, were recruited (4 DG, 4 diabetics, and 4 healthy volunteers) for 11C‐ER 176 PET/CT scanning. The standardized uptake value (SUVmax) in the gastric fundus, body, pylorus, and descending part of the duodenum were compared between three groups using Kruskal‐Wallis test to perform the comparisons, and a p‐value of 0.05 was considered statistically significant.Key ResultsAge was comparable among the three groups with a median of 53 years. The uptake was higher in pylorus in diabetics compared to DG and healthy (SUVmax healthy 4.6 ± 0.2, diabetics 8.4 ± 4.1, DG 5.5 ± 1.0, p = 0.04). The uptake was similar in gastric fundus (9.0 ± 1.6, 13.1 ± 8.3, 7.8 ± 1.9 respectively, p = 0.3), body (7.7 ± 1.9, 13 ± 9.2, 7.8 ± 1.9 respectively, p = 0.8), and duodenum (6.2 ± 2.1, 9.5 ± 6.8, 7.0 ± 1.8 respectively, p = 0.6). No correlation was observed between SUVmax uptake and either HbA1C or fasting blood glucose.Conclusions and InferencesFemale diabetic gastroparesis patients did not demonstrate increased TSPO ligand 11C‐ER 176 uptake in the stomach. Possible explanations include lack of specificity of ligand for specific macrophage phenotypes in DG, sex effect, or small sample size. Further studies investigating non‐invasive ways of analyzing immune dysregulation in neurogastrointestinal disorders are warranted.
Adipose Tissue Analysis Toolkit (ATAT) for automated analysis of adipocyte size and extracellular matrix in white adipose tissue
Robino, Jacob J., Plekhanov, Alexander, Jensen, Michael D. , Scherer, Philipp E. , Roberts, Charles T. , Varlamov, Oleg , Jensen, Michael , Scherer, Philipp E , Varlamov, Oleg , Zhu, Qingzhang

Obesity | February 7, 2024 | Volume: 32 | Issue: 4 | Pages: 723-732

10.1002/oby.23992 | PMID 38321231 Get It

Abstract Objective The pathological expansion of white adipose tissue (WAT) in obesity involves adipocyte hypertrophy accompanied by expansion of the collagen‐rich pericellular extracellular matrix (ECM) and development of crown‐like structures (CLS). Traditionally, WAT morphology is assessed through immunohistochemical analysis of WAT sections. However, manual analysis of large histological sections is time‐consuming, and the available digital tools for analyzing adipocyte size and pericellular ECM are limited. To address this gap, the authors developed the Adipose Tissue Analysis Toolkit (ATAT), an ImageJ plugin facilitating analysis of adipocyte size, WAT ECM, and CLS. Methods and Results ATAT utilizes local and image‐level differentials in pixel intensity to independently threshold image background, distinguishing adipocyte‐free tissue without user input. It accurately captures adipocytes in histological sections stained with common dyes and automates the analysis of adipocyte cross‐sectional area, total‐field, and localized region‐of‐interest ECM. ATAT allows fully automated batch analysis of histological images using default or user‐defined adipocyte detection parameters. Conclusions ATAT provides several advantages over existing WAT image analysis tools, enabling high‐throughput analyses of adipocyte‐specific parameters and facilitating the assessment of ECM changes associated with WAT remodeling due to weight changes and other pathophysiological alterations that affect WAT function.